학술논문
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFRMutation–Positive NSCLC Patients
Document Type
Article
Author
Scagliotti, Giorgio; Moro-Sibilot, Denis; Kollmeier, Jens; Favaretto, Adolfo; Cho, Eun Kyung; Grosch, Heidrun; Kimmich, Martin; Girard, Nicolas; Tsai, Chun-Ming; Hsia, Te-Chun; Brighenti, Matteo; Schumann, Christian; Wang, Xuejing Aimee; Wijayawardana, Sameera R.; Gruver, Aaron M.; Wallin, Johan; Mansouri, Kambiz; Wacheck, Volker; Chang, Gee-Chen
Source
Journal of Thoracic Oncology; January 2020, Vol. 15 Issue: 1 p80-90, 11p
Subject
Language
ISSN
15560864; 15561380
Abstract
The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.